Nanovibronix Secures $50M Investment to Revolutionize Low-Intensity Ultrasound Medical Devices

NanoVibronix Inc., a pioneering medical device company headquartered in Elmsford, NY, has successfully raised $50,000,000 in its latest funding round—a significant milestone that highlights the continued investor confidence in its innovative approach to therapeutic ultrasound technology. This robust influx of capital is slated to fuel expansive research and development initiatives, accelerate regulatory strategies, and expand market reach for its proprietary low intensity acoustic technology. NanoVibronix has established itself as a leader through its patented ability to create miniature transducers capable of transmitting low-frequency, low-intensity ultrasound through flexible material surfaces; a breakthrough that enables the development of cost-effective, non-invasive medical solutions. Among its noteworthy products, the patch-based PainShield® has already garnered FDA clearance, providing patients and clinicians with a reliable option for pain management, while its catheter-based offering, the Cathbot™, continues to demonstrate promising potential in advanced therapeutic applications. The fresh capital will not only support the refinement of these groundbreaking technologies but will also pave the way for expanding production capacities, enhancing clinical research efforts, and integrating strategic marketing initiatives across global markets. Moreover, with its subsidiary NanoVibronix Ltd. operating from Nesher, Israel, the company is well-positioned to leverage international expertise and foster collaborations that could further transform the landscape of therapeutic ultrasound applications. This new investment marks a pivotal moment for NanoVibronix as it continues to push the boundaries of medical innovation, solidifying its commitment to delivering high-quality, accessible healthcare solutions that can make a meaningful difference in patient lives.